Insiders · SYRS

SYRS insider transactions

Syros Pharmaceuticals Inc. (SYRS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for SYRS

• 551d
  Director Simonian Nancy A sold $10,016 worth of shares (37,070 units at $0.27), decreasing direct ownership by 90% to 4,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 558d
  Director Simonian Nancy A sold $35,739 worth of shares (134,713 units at $0.27), decreasing direct ownership by 77% to 41,070 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 565d
  Chief Development Officer Stephens Kristin sold $7,949 worth of shares (36,133 units at $0.22), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 565d
  Chief Legal & Compliance Offic Quirk Gerald E sold $10,321 worth of shares (46,657 units at $0.22), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 565d
  Chief Medical Officer Roth David sold $2,382 worth of shares (12,099 units at $0.20), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 565d
  President & CEO Chee Conley sold $26,932 worth of shares (134,797 units at $0.20), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 565d
  Chief Financial Officer Haas Jason sold $28,980 worth of shares (137,803 units at $0.21), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 581d
  Director Simonian Nancy A converted options into 40,125 shares, increasing direct ownership by 30% to 175,783 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 581d
  Chief Medical Officer Roth David converted options into 18,875 shares and covered exercise/tax liability with 6,776 shares (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 581d
  Chief Financial Officer Haas Jason converted options into 18,875 shares and covered exercise/tax liability with 5,624 shares, increasing direct ownership by 11% to 137,803 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 581d
  President & CEO Chee Conley covered exercise/tax liability with 8,707 shares and converted options into 17,000 shares, increasing direct ownership by 7% to 130,797 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 581d
  Chief Development Officer Stephens Kristin converted options into 17,000 shares and covered exercise/tax liability with 6,104 shares, increasing direct ownership by 43% to 36,133 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 614d
  Chief Legal & Compliance Offic Quirk Gerald E converted options into 10,000 shares and covered exercise/tax liability with 3,100 shares, increasing direct ownership by 17% to 46,657 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 628d
  Director Akkaraju Srinivas converted options into 2,667 shares, increasing direct ownership by 40% to 9,333 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 628d
  Director Young Richard A converted options into 2,667 shares, increasing direct ownership by 33% to 10,667 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 634d
  Chief Financial Officer Haas Jason bought $161,240 worth of shares (100,000 units at $1.61), increasing direct ownership by 407% to 124,552 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 634d
  President & CEO Chee Conley bought $160,680 worth of shares (100,000 units at $1.61), increasing direct ownership by 444% to 122,504 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 706d
  Director Young Richard A sold $178,365 worth of shares (34,837 units at $5.12), decreasing direct ownership by 81% to 8,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Simonian Nancy A was granted 4,000 shares, increasing direct ownership by 3% to 135,658 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Oh Andrew M. was granted 4,000 shares, increasing direct ownership by 33% to 16,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Young Richard A was granted 4,000 shares, increasing direct ownership by 10% to 42,837 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  SEC Form 4 filed by Dunsire Deborah

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Tyson Timothy was granted 4,000 shares, increasing direct ownership by 14% to 33,189 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Eckhardt Sue Gail was granted 4,000 shares, increasing direct ownership by 33% to 16,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  SEC Form 4 filed by Akkaraju Srinivas

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Wirth Peter was granted 4,000 shares, increasing direct ownership by 33% to 16,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 731d
  Fanucci Marsha was granted 4,000 shares, increasing direct ownership by 33% to 16,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 734d
  Dunsire Deborah converted options into 4,000 shares, increasing direct ownership by 50% to 12,000 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 734d
  Akkaraju Srinivas converted options into 4,000 shares, increasing direct ownership by 150% to 6,666 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 794d
  Roth David sold $51,732 worth of shares (10,451 units at $4.95), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Stephens Kristin converted options into 13,666 shares and covered exercise/tax liability with 4,218 shares, increasing direct ownership by 60% to 25,237 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Simonian Nancy A converted options into 45,566 shares and covered exercise/tax liability with 14,052 shares, increasing direct ownership by 31% to 131,658 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Roth David covered exercise/tax liability with 4,732 shares, sold $747 worth of shares (150 units at $4.98) and converted options into 15,333 shares (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Quirk Gerald E converted options into 22,500 shares and covered exercise/tax liability with 7,046 shares, increasing direct ownership by 64% to 39,757 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Haas Jason covered exercise/tax liability with 4,732 shares and converted options into 15,333 shares, increasing direct ownership by 76% to 24,552 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 797d
  Chee Conley converted options into 13,666 shares and covered exercise/tax liability with 3,500 shares, increasing direct ownership by 82% to 22,504 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 895d
  Akkaraju Srinivas bought $3,999,998 worth of shares (904,977 units at $4.42) (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 907d
  Roth David sold $31,121 worth of shares (6,287 units at $4.95), closing all direct ownership in the company (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 913d
  Roth David sold $24,834 worth of shares (6,287 units at $3.95), decreasing direct ownership by 50% to 6,287 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 916d
  SEC Form 4 filed by Chee Conley

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 916d
  SEC Form 4 filed by Simonian Nancy A

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 949d
  Simonian Nancy A converted options into 40,125 shares and covered exercise/tax liability with 13,401 shares, increasing direct ownership by 36% to 100,144 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 949d
  Haas Jason converted options into 18,875 shares and covered exercise/tax liability with 6,301 shares, increasing direct ownership by 913% to 13,951 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 949d
  Roth David converted options into 18,875 shares and covered exercise/tax liability with 6,301 shares (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 949d
  Stephens Kristin converted options into 17,000 shares and covered exercise/tax liability with 5,676 shares, increasing direct ownership by 254% to 15,789 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 949d
  Chee Conley converted options into 17,000 shares and covered exercise/tax liability with 6,004 shares, increasing direct ownership by 819% to 12,338 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 962d
  Quirk Gerald E converted options into 22,500 shares and covered exercise/tax liability with 6,897 shares, increasing direct ownership by 179% to 24,303 units (SEC Form 4)

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 993d
  SEC Form 4: Young Richard A converted options into 2,666 shares, increasing direct ownership by 7% to 38,837 units

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 993d
  SEC Form 4: Alles Mark J converted options into 2,666 shares, increasing direct ownership by 267% to 3,666 units

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 993d
  SEC Form 4: Akkaraju Srinivas converted options into 2,666 shares

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 998d
  SEC Form 4 filed by Quirk Gerald E

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1041d
  SEC Form 4: Roth David sold $29,025 worth of shares (7,348 units at $3.95), closing all direct ownership in the company

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1056d
  SEC Form 4 filed by Olson Eric R

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Young Richard A

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Wirth Peter

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Tyson Timothy

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Oh Andrew M.

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Fanucci Marsha

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Eckhardt Sue Gail

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)
• 1102d
  SEC Form 4 filed by Dunsire Deborah

  4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)